Profile data is unavailable for this security.
About the company
Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. It offers vitamins, minerals, supplements and neurological products. It has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. It supplies APIs for anti-retroviral, anti-malarial and others.
- Revenue in INR (TTM)160.95bn
- Net income in INR-3.24bn
- Incorporated1983
- Employees19.79k
- LocationLupin LtdB/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E)MUMBAI 400051IndiaIND
- Phone+91 2 266402222
- Fax+91 2 266402130
- Websitehttp://www.lupin.com/
More ▼
Mergers & acquisitions
| Acquired company | LUPIN:NSI since announced | Transaction value |
|---|---|---|
| Boehringer Ingelheim International GmbH-Ondero & Ondero Met Brands | -8.37% | -- |
Data delayed at least 15 minutes, as of Mar 24 2023 10:21 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J B Chemicals and Pharmaceuticals Ltd | 30.12bn | 4.07bn | 151.51bn | 4.34k | 37.45 | -- | 29.59 | 5.03 | 52.29 | 52.29 | 386.99 | -- | -- | -- | -- | 6,939,050.00 | -- | 14.74 | -- | 17.47 | 63.27 | 59.83 | 13.53 | 15.46 | -- | 23.30 | -- | 29.57 | 18.69 | 12.20 | -13.98 | 15.93 | 35.25 | 75.18 |
| Ajanta Pharma Ltd | 37.31bn | 6.17bn | 156.42bn | 7.23k | 25.43 | -- | 20.97 | 4.19 | 48.01 | 48.01 | 290.34 | -- | -- | -- | -- | 5,157,714.00 | -- | 17.70 | -- | 21.07 | 71.89 | 75.70 | 16.54 | 20.68 | -- | -- | -- | 15.35 | 15.62 | 10.79 | 8.99 | 7.05 | -13.03 | -6.08 |
| Piramal Enterprises Ltd | 104.23bn | 102.74bn | 159.99bn | 13.56k | 1.57 | -- | 1.51 | 1.53 | 430.44 | 430.44 | 436.59 | -- | -- | -- | -- | 7,686,321.00 | -- | 2.44 | -- | 3.40 | 62.80 | 82.35 | 98.96 | 15.05 | -- | 1.45 | -- | 30.48 | 9.24 | 10.36 | 44.34 | 8.96 | -15.09 | 10.12 |
| Pfizer Limited | 24.02bn | 6.20bn | 161.28bn | 2.29k | 26.01 | -- | 22.05 | 6.72 | 135.52 | 135.52 | 524.87 | -- | -- | -- | -- | 10,511,070.00 | -- | 12.76 | -- | 16.53 | 64.72 | 60.68 | 25.82 | 21.77 | -- | 46.21 | -- | 84.05 | 16.64 | 5.04 | 23.10 | 12.71 | -9.55 | 18.47 |
| Laurus Labs Ltd | 60.84bn | 9.18bn | 164.40bn | 5.13k | 17.93 | -- | 13.43 | 2.70 | 17.02 | 17.02 | 112.84 | -- | -- | -- | -- | 11,858,270.00 | -- | 11.29 | -- | 19.65 | 54.59 | 47.95 | 15.14 | 13.77 | -- | 9.94 | -- | 11.74 | 2.54 | 20.64 | -15.87 | 34.18 | 25.87 | 46.14 |
| IPCA Laboratories Ltd | 60.22bn | 5.25bn | 198.61bn | 15.16k | 37.84 | -- | 24.96 | 3.30 | 20.69 | 20.69 | 237.30 | -- | -- | -- | -- | 3,973,468.00 | -- | 12.86 | -- | 16.66 | 64.44 | 59.86 | 9.01 | 14.45 | -- | 18.13 | -- | 10.26 | 7.56 | 12.67 | -22.45 | 35.36 | 28.57 | 51.57 |
| Gland Pharma Ltd | 39.43bn | 9.89bn | 205.17bn | 4.64k | 20.79 | -- | 18.18 | 5.20 | 59.91 | 59.91 | 239.01 | -- | -- | -- | -- | 8,498,823.00 | -- | -- | -- | -- | 52.67 | -- | 25.07 | -- | -- | 146.39 | -- | -- | 27.08 | -- | 21.54 | -- | -- | -- |
| GlaxoSmithKline Pharmaceuticals Limited | 32.74bn | 4.20bn | 217.37bn | 3.84k | 51.82 | -- | 44.97 | 6.64 | 24.76 | 100.12 | 193.23 | -- | -- | -- | -- | 8,525,779.00 | -- | 8.78 | -- | 13.95 | 60.55 | 53.73 | 12.81 | 10.19 | -- | 519.35 | -- | 212.53 | 12.05 | 1.79 | 32.55 | 2.48 | -35.25 | 14.87 |
| Syngene International Ltd | 29.57bn | 4.33bn | 230.41bn | 5.98k | 52.91 | -- | 29.37 | 7.79 | 10.90 | 10.90 | 74.13 | -- | -- | -- | -- | 4,948,285.00 | -- | 9.20 | -- | 12.66 | 73.58 | 70.63 | 14.66 | 18.41 | -- | 7.95 | -- | -- | 19.22 | 16.74 | -2.25 | 6.62 | 9.19 | 0.00 |
| Biocon Ltd | 98.09bn | 3.88bn | 243.14bn | 3.20k | 62.94 | -- | 16.50 | 2.48 | 3.24 | 3.24 | 81.89 | -- | -- | -- | -- | 30,624,730.00 | -- | 5.67 | -- | 7.86 | 66.74 | 60.43 | 5.22 | 12.71 | -- | 3.17 | -- | 5.23 | 14.57 | 15.85 | -12.44 | 1.16 | 20.36 | 0.00 |
| Aurobindo Pharma Ltd | 241.92bn | 19.98bn | 280.52bn | 21.00k | 14.05 | -- | 8.90 | 1.16 | 34.09 | 34.09 | 412.78 | -- | -- | -- | -- | 11,519,900.00 | -- | 11.53 | -- | 18.30 | 55.00 | 53.95 | 8.26 | 14.54 | -- | 39.07 | -- | 6.66 | -5.32 | 9.22 | -50.36 | 2.84 | 9.81 | 29.20 |
| Lupin Ltd | 160.95bn | -3.24bn | 299.76bn | 19.79k | -- | -- | 47.01 | 1.86 | -7.15 | -7.15 | 353.59 | -- | -- | -- | -- | 8,133,110.00 | -- | 0.0772 | -- | 0.1081 | 58.61 | 61.21 | -1.90 | 0.1267 | -- | 5.03 | -- | 2,376.12 | 8.19 | -1.28 | -225.61 | -- | -19.25 | -11.81 |
| Alkem Laboratories Ltd | 111.81bn | 10.21bn | 384.19bn | 16.97k | 37.64 | -- | 28.20 | 3.44 | 85.38 | 85.38 | 935.18 | -- | -- | -- | -- | 6,589,957.00 | -- | 12.30 | -- | 18.19 | 58.12 | 59.27 | 9.37 | 14.07 | -- | 11.59 | -- | 25.58 | 19.96 | 12.69 | 3.82 | 13.03 | -12.07 | 17.78 |
Data as of Mar 24 2023. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR
26.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Mar 2022 | 38.12m | 8.38% |
| ICICI Prudential Asset Management Co. Ltd.as of 19 May 2022 | 23.07m | 5.07% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 28 Feb 2023 | 18.30m | 4.02% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 28 Feb 2023 | 8.75m | 1.92% |
| The Vanguard Group, Inc.as of 03 Mar 2023 | 7.57m | 1.66% |
| Norges Bank Investment Managementas of 31 Mar 2022 | 6.05m | 1.33% |
| BlackRock Fund Advisorsas of 01 Mar 2023 | 5.50m | 1.21% |
| SBI Funds Management Pvt Ltd.as of 28 Feb 2023 | 5.11m | 1.12% |
| DSP Investment Managers Pvt. Ltd.as of 28 Feb 2023 | 4.62m | 1.02% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 28 Feb 2023 | 4.49m | 0.99% |
More ▼
Data from 31 Dec 2022 - 16 Mar 2023Source: FactSet Research Systems Inc.
